These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9520169)

  • 1. Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine.
    Rubio A; Leal M; Rey C; Pineda JA; Sanchez-Quijano A; Lissen E
    AIDS; 1998 Mar; 12(4):395-8. PubMed ID: 9520169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.
    Eron JJ
    AIDS; 1996 Dec; 10 Suppl 5():S11-9. PubMed ID: 9030391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and application of a genotypic AZT resistance assay: quantitative assessment of the resistance profile of clinical samples and the relative predictive ability of a resistance index.
    Kyriakides TC; Heimer RR
    J Acquir Immune Defic Syndr; 2001 Nov; 28(3):211-20. PubMed ID: 11694826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study.
    Leal M; Torres Y; Medrano FJ; Rey C; Caruz A; Sánchez-Quijano A; Lissen E
    Eur J Clin Invest; 1996 Oct; 26(10):923-8. PubMed ID: 8911867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
    Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
    AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
    Kahn J; Lagakos S; Wulfsohn M; Cherng D; Miller M; Cherrington J; Hardy D; Beall G; Cooper R; Murphy R; Basgoz N; Ng E; Deeks S; Winslow D; Toole JJ; Coakley D
    JAMA; 1999 Dec 22-29; 282(24):2305-12. PubMed ID: 10612317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
    AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.